MedTechIQ Selected as "Referring Entity" to NextTechs Technology Marketplace!!!

[CC-Conrad Clyburn-MedForeSight]

The Clymer Group™, LLC is proud to announce that it has been formally approved as a “Qualified Referring Entity” by NextTechs Technologies, LLC, for its technology & intellectual property (IP) marketplace. Commercialization is achieved through securing a consistent customer base. This requires capital.

The largest, most ignored, source of investment capital for emerging technology is corporate. It exceeds Angel & early stage venture funds combined. NextTechs secures capital and customers for promising new technologies by issuing Technology & Patent Searches. It then intermediates corporate investment for technology emerging from academia, industry and government via their network of direct relationships with over 300 marketplace participants in 41 different industries and 150 research domains. Successful searches have included securing new technology for Eli Lilly, Roche & Siemens.

The NextTechs corporate investor base may also take its involvement one step beyond, by entering into additional value generating relationships that greatly mitigate technology development risk. This added support is powerful, and can include:

- joint development agreements
- marketing arrangements
- licensing contracts
- or other business development activities

NextTechs is a key intermediary in the global patent marketplace. They are currently working with Sovereign Wealth and other private equity funders, one of which plans to invest over $1.0 billion in the next three years to purchase patents for local commercialization. Patent acquisition is perfect for investigators who are not interested in the heavy lifting that “bringing-to-market” requires. This service will enable public and private research entities to monetize their patent portfolios, and reinvest their resources into newer, challenging, and perhaps even more promising areas. The bottom-line benefit to NextTechs clients is not solely financial. With a more efficient market, timelines contract as technologies develop more rapidly, sales are achieved earlier, and investment capital is more easily secured. Early stage direct corporate involvement also permits quicker market establishment, enhanced valuation and accelerated liquidity events.

This is a very BIG DEAL (double entendre intentional). The R&D arena is undergoing a radical transformation. The 21st century model demands radical collaboration via a global “knowledge commons” mediated over ubiquitous, nearly cost-free communications channels, like MedTechIQ. Even corporate behemoths like Microsoft, Pfizer and Intel are discovering that they must ‘open up’ to succeed! Well before the current economic crisis, the die was already cast for predicting success or failure. In a financial ecosystem starved for liquidity, collaboration has only become more important. The marketplace will render both indictment and verdict to those enterprises that cling to the “old school” thinking of solely depending on in-house creativity, and jealously guarding all intellectual property. Though much of the healthcare environment is viewed as idiosyncratic, it is not immune to this inescapable trend. Entities outside of the medical technology space currently exist to provide reconciliation between problems in search of solutions and solutions in search of problems. Many are succeeding, but none, to our knowledge, functions over a social network like MedTechIQ. We feel strongly that this ups the ante in a substantive way.

Consequentially, MedTechIQ members will now have access to the fully arrayed NextTechs network and its services via The Clymer Group. You will be able to refer proposals, in response to NextTechs solicitations, or “push” promising technologies to them for their consideration. The first of these search requests has been posted. Many more will follow. Quite simply, we believe this to be the inauguration of an enjoyable, intellectually challenging, and profitable journey. WELCOME!